Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Oct-Dec;16(4):308-313.
doi: 10.1590/1677-5449.007817.

Mecanismos do tromboembolismo venoso no câncer: uma revisão da literatura

[Article in Portuguese]
Marcos José Pereira Renni  1 , Mônica Hermida Cerqueira  2 , Ingrid de Araújo Trugilho  1 , Mario Lúcio Cordeiro Araujo Junior  1 , Marcos Arêas Marques  3 , Hilton Augusto Koch  4
Affiliations
Review

Mecanismos do tromboembolismo venoso no câncer: uma revisão da literatura

[Article in Portuguese]
Marcos José Pereira Renni et al. J Vasc Bras. 2017 Oct-Dec.

Abstract
in English, Portuguese

Abstract: There is a strong relationship between venous thromboembolism and cancer. Patients with tumors have a higher incidence of thromboembolic events in their clinical evolution. The occurrence of such events is considered a negative predictive marker in this group of patients. Thus, we aim to review activation of coagulation mechanisms in this group of patients. Activation of coagulation mechanisms in cancer patients is a complex and multifactorial process, related to tumor characteristics, clinical staging, the disease’s aggressiveness, tumor sites, and additional factors caused by disease progression. New biomarkers have been under investigation over the years in the attempt to correlate them to the risk of thrombosis, aiming to develop interventions that improve the clinical evolution of these cancer patients.

Existe uma estreita relação entre o tromboembolismo venoso e o câncer. Pacientes com neoplasias apresentam maior incidência de eventos tromboembólicos em sua evolução clínica. A ocorrência desses eventos é considerada um marcador preditivo negativo nesse grupo de pacientes. Revisamos, então, a ativação dos mecanismos de coagulação neste grupo de pacientes. Trata-se de um processo complexo e multifatorial, relacionado tanto a características tumorais, estadiamento clínico, agressividade da doença e sítios tumorais, dentre outros. Novos biomarcadores vêm sendo pesquisados ao longo dos anos na tentativa de correlacioná-los ao risco trombótico, visando uma intervenção que melhore a evolução clínica desses pacientes oncológicos.

PubMed Disclaimer

Conflict of interest statement

Conflito de interesse: Os autores declararam não haver conflitos de interesse que precisam ser informados.

References

    1. Khorana AA. Risk assessment for cancer-associated thrombosis: what is the best approach? Thromb Res. 2012;129(Suppl 1):10–15. http://dx.doi.org/10.1016/S0049-3848(12)70009-9 - DOI - PubMed
    1. Lee AYY. Epidemiology and management of venous thromboembolism in patients with cancer. Thromb Res. 2003;110(4):167–172. http://dx.doi.org/10.1016/S0049-3848(03)00347-5 - DOI - PubMed
    1. Sørensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med. 1998;338(17):1169–1173. http://dx.doi.org/10.1056/NEJM199804233381701 - DOI - PubMed
    1. Furie B, Furie BC. Cancer-associated thrombosis. Blood Cells Mol Dis. 2006;36(2):177–181. http://dx.doi.org/10.1016/j.bcmd.2005.12.018 - DOI - PubMed
    1. Cogo A, Bernardi E, Prandoni P, et al. Acquired risk factors for deep-vein thrombosis in symptomatic outpatients. Arch Intern Med. 1994;154(2):164–168. http://dx.doi.org/10.1001/archinte.1994.00420020066008 - DOI - PubMed

LinkOut - more resources